Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 7/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192341 | 1.00 | ALDH1A1 (0.64) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL31255351 | 0.91 | ALDH1A1 (0.69) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL22905145 | 0.91 | ALDH1A1 (0.64) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL21362723 | 0.91 | ALDH1A1 (0.64) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL472602 | 0.91 | ALDH1A1 (0.64) | ALDH1A1GAATSHREPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL27603388 | 0.90 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL6888432 | 0.90 | ALDH1A1 (0.70) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3948461 | 0.85 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL381922 | 0.85 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3948456 | 0.85 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459535-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778951-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20130324530-A1 | 3-(AMINOARYL)-PYRIDINE COMPOUNDS | NOVARTIS AG | 2013-12-05 | — | — | US | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| EP-2640702-A1 | 3-(AMINOARYL)-PYRIDINE COMPOUNDS | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8415381-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| WO-2012101065-A2 | PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101066-A1 | PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459535-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012066070-A1 | 3-(AMINOARYL)-PYRIDINE COMPOUNDS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012661-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | ALDH1A1 2639/4885GAA 1035/4885TSHR 2674/4885 |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | ALDH1A1 2639/4885GAA 1035/4885TSHR 2674/4885 |
| US-20130324530-A1 | 3-(AMINOARYL)-PYRIDINE COMPOUNDS | CDK9, CDK19, CDK3 | ALDH1A1 1949/4885GAA 1354/4885TSHR 3274/4885 |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | CDK9, CDK19, CDK3 | ALDH1A1 2639/4885GAA 1035/4885TSHR 2674/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | ALDH1A1 2220/4885GAA 2215/4885TSHR 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.